Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly,Alexandra C. Greb,Lindsay P. Cameron,Jonathan M. Wong,Eden V. Barragan,Paige C. Wilson,Kyle F. Burbach,Sina Soltanzadeh Zarandi,Alexander Sood,Michael R. Paddy,Whitney C. Duim,Megan Y. Dennis,A. Kimberley McAllister,Kassandra M. Ori-McKenney,John A. Gray,David E. Olson +15 more
Reads0
Chats0
TLDR
It is reported that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo.About:
This article is published in Cell Reports.The article was published on 2018-06-12 and is currently open access. It has received 436 citations till now.read more
Citations
More filters
Posted ContentDOI
Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice
Christopher Thomas,C Blanco-Duque,B Bréant,Guy M. Goodwin,Trevor Sharp,David M. Bannerman,Vladyslav V. Vyazovskiy +6 more
TL;DR: In this article, chronic in vivo electrophysiological recordings were obtained in mice to track sleep-wake architecture and cortical activity after psilocin injection, and it was concluded that psilocalin affects both global vigilance state control and local sleep homeostasis, an effect which may be relevant for its antidepressant efficacy.
Journal ArticleDOI
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
Edward Jacobs,Edward Jacobs +1 more
TL;DR: Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential.
Posted Content
5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology
TL;DR: It is suggested that BDNF overexpression resulting from mTOR activation mediates both structural and functional plasticity, resulting in connectivity changes among high-level cognitive networks such as the Default Mode Network, finally leading to an increased and long-lasting psychological flexibility.
Journal ArticleDOI
Stress-mediated hyperactivity and anhedonia resistant to diazepam and fluoxetine in drosophila
TL;DR: This study provides a time-efficient model system for the study of stress-mediated hyperactivity and anhedonia-like state resistant to fluoxetine and diazepam in Drosophila.
Journal ArticleDOI
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
TL;DR: The potential for use of psilocybin and psilocin as a treatment agent in neuropsychiatry has been investigated in this article , where the potential for harm is also assessed.
References
More filters
Journal ArticleDOI
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
Harvey Whiteford,Harvey Whiteford,Louisa Degenhardt,Louisa Degenhardt,Juergen Rehm,Juergen Rehm,Amanda J Baxter,Amanda J Baxter,Alize J. Ferrari,Alize J. Ferrari,Holly E. Erskine,Holly E. Erskine,Fiona J Charlson,Fiona J Charlson,Rosana E. Norman,Rosana E. Norman,Abraham D. Flaxman,Nicole E. Johns,Roy Burstein,Christopher J L Murray,Theo Vos +20 more
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) as discussed by the authors was used to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
A simple practice guide for dose conversion between animals and human.
Anroop B. Nair,Shery Jacob +1 more
TL;DR: This review provides basic information about translation of doses between species and estimation of starting dose for clinical trials using allometric scaling and the method of calculation of injection volume for parenteral formulation based on human equivalent dose.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.
Journal ArticleDOI
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate,Jaskaran Singh,Paul J. Carlson,Nancy E. Brutsche,Rezvan Ameli,David A. Luckenbaugh,Dennis S. Charney,Husseini K. Manji +7 more
TL;DR: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.